GlassScriptPhysician profile
Ross A Reynolds
NPI 1104247410
$1,236.93
in general payments reported to CMS, 2019-2025
15 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.45 · 2022: $313 · 2023: $311 · 2024: $361 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.53 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $365.08 | 2021-2025 | |
| Boston Scientific Corporation | $169.13 | 2024 | Exalt Model D, Captiflex |
| Janssen Biotech, INC. | $141.58 | 2023-2025 | Stelara, Tremfya |
| Janssen Scientific Affairs, LLC | $120.85 | 2022 | |
| Novo Nordisk INC | $120.68 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.33 | 2022-2023 | Xifaxan |
| Genzyme Corporation | $37.51 | 2022-2023 | |
| Madrigal Pharmaceuticals | $32.54 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $28.81 | 2024-2025 | Entyvio, Eohilia |
| Ipsen Biopharmaceuticals, INC | $22.06 | 2025 | Iqirvo |
| Celgene Corporation | $18.84 | 2024 | Zeposia |
| Braintree Laboratories, INC. | $17.27 | 2024 | Sutab, Suflave |
| Fresenius Kabi USA, LLC | $15.83 | 2023 | Idacio |
| Ferring Pharmaceuticals INC. | $14.79 | 2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $14.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Reynolds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.